B+
Bull case
25%
Probability
Target price
$205.00
Analysis reference price unavailable
Analysis 2026-05-18 · RankAlpha Sentiment Codex
DHR
DanaherDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$168.00
Analysis reference price unavailable
Analysis 2026-05-18 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$132.00
Analysis reference price unavailable
Analysis 2026-05-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-18
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+44.4
Score
AI commentary
The tape is modestly constructive but still tentative: Danaher delivered a Q1 beat-and-raise and Masimo stockholder approval removed one deal hurdle, but the forward catalyst set is now mostly regulatory clearance, closing, and post-close execution. Core growth was still only 0.5%, Diagnostics/Cepheid remains the weak spot, and the packet does not provide a usable analyst revision wave, price-reaction confirmation, or social-coverage signal. This should remain a lower-conviction monitoring view rather than a catalyst-driven bullish call.
RankAlpha Sentiment Codex - 2026-05-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-26catalystQ1 beat-and-raise kept 2026 EPS momentum intactMedium impact
Danaher reported Q1 2026 revenue of $6.0 billion (+3.5% y/y), adjusted diluted EPS of $2.06 (+9.5%), core revenue of +0.5%, operating cash flow of $1.3 billion, and free cash flow of $1.1 billion. Management raised full-year 2026 adjusted EPS guidance to $8.35-$8.55 while keeping core revenue guidance at +3% to +6%; Bioprocessing strength and better Life Sciences offset a lighter Cepheid respiratory season. This is supportive, but still a monitoring point because broad core growth remains thin. [#10-Q-2026-04-21]
2026-09-30eventMasimo transaction moves into regulatory-clearance and 2026 close windowMedium impact
Danaher agreed to acquire Masimo for $180.00 per share in cash, with closing subject to customary conditions including HSR expiration and required non-U.S. antitrust and foreign-direct-investment approvals. Masimo later announced stockholder approval, leaving regulatory clearance and closing execution as the main forward company-specific catalyst for 2026. [#PR-2026-02-17] [#PR-2026-05-04]
2027-12-31catalystDiagnostics mix can improve if Masimo closes and synergy assumptions prove durableHigh impact
Danaher has framed Masimo as a way to strengthen Diagnostics, with Masimo expected to be accretive to adjusted EPS in the first full year after close and to contribute longer-term cost and revenue synergies. This remains an execution-dependent long catalyst because the deal still needs to close and the synergy case must be proven after integration. [#PR-2026-02-17]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-18 • Updated nightlySource: Internal modelMethodology